79 studies found for:    "Kidney Diseases, Cystic"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Evaluation of Complex Renal Cyst With CEUS/Functional MRI Versus CT
Conditions: Cystic Renal Diseases;   Kidney Neoplasms
Interventions: Other: Blood/urine sampling;   Other: Conventional routine CT examination;   Other: Contrast-enhanced renal ultrasonography (CEUS);   Other: Functional MRI
2 Recruiting UAB HRFD Core Center: Core A: The Hepato/Renal Fibrocystic Diseases Translational Resource
Conditions: Hepato/Renal Fibrocystic Disease;   Autosomal Recessive Polycystic Kidney Disease;   Joubert Syndrome;   Bardet Biedl Syndrome;   Meckel-Gruber Syndrome;   Congenital Hepatic Fibrosis;   Caroli Syndrome;   Oro-Facial-Digital Syndrome Type I;   Nephronophthisis;   Glomerulocystic Kidney Disease
Intervention:
3 Unknown  UAB Recessive PKD Research and Translational Core Center
Condition: Autosomal Recessive Polycystic Kidney Disease
Intervention:
4 Completed Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Condition: Polycystic Kidney, Autosomal Dominant
Interventions: Drug: pravastatin;   Drug: Placebo
5 Completed Assessment of the Prevalence of Genes AHI1, NPHP1 and CEP290 in Joubert Syndrome
Conditions: Joubert Syndrome;   Cerebello-oculo-renal Syndromes
Intervention: Biological: Whole blood sample
6 Terminated Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency
Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: Drug: Sirolimus;   Drug: conventional therapy
7 Recruiting Polycystic Kidney Disease Data Repository
Condition: Polycystic Kidney Disease
Intervention:
8 Completed Lanreotide as Treatment of Polycystic Livers
Conditions: Polycystic Liver Disease;   Hepatomegaly;   Liver Diseases;   Polycystic Kidney, Autosomal Dominant
Interventions: Drug: Placebo;   Drug: Lanreotide
9 Recruiting Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease
Conditions: Chronic Kidney Disease;   Autosomal Dominant Polycystic Kidney Disease
Interventions: Drug: Tolvaptan (OPC-41061);   Drug: Placebo
10 Recruiting The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients
Condition: Autosomal Dominant Polycystic Kidney Disease
Interventions: Drug: Everolimus;   Drug: Calcineurin inhibitors maintenance
11 Active, not recruiting A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention: Drug: OPC-41061
12 Recruiting Clinical and Molecular Investigations Into Ciliopathies
Conditions: Autosomal Recessive Polycystic Kidney Disease;   Congenital Hepatic Fibrosis;   Caroli's Disease;   Polycystic Kidney Disease;   Joubert Syndrome;   Cerebro-Oculo-Renal Syndromes;   COACH Syndrome;   Senior-Loken Syndrome;   Dekaban-Arima Syndrome;   Cogan Oculomotor Apraxia;   Nephronophthisis;   Bardet-Biedl Syndrome;   Alstrom Syndrome;   Oral-Facial-Digital Syndrome
Intervention:
13 Completed
Has Results
HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A
Condition: Kidney, Polycystic
Interventions: Drug: Lisinopril;   Drug: Telmisartan;   Drug: Placebo;   Other: Standard Blood Pressure Control;   Other: Low Blood Pressure Control
14 Active, not recruiting Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency
Condition: Autosomal Dominant Polycystic Kidney Disease.
Interventions: Drug: Octreotide-LAR;   Other: Saline solution.
15 Completed 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Condition: Autosomal Dominant Polycystic Kidney Disease
Interventions: Drug: Tolvaptan MR;   Drug: Tolvaptan IR;   Drug: Placebo
16 Recruiting Study of Lanreotide to Treat Polycystic Kidney Disease
Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Intervention: Drug: Lanreotide
17 Completed
Has Results
Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease
Condition: Autosomal Dominant Polycystic Kidney Disease
Interventions: Drug: Placebo;   Drug: Everolimus
18 Recruiting Pasireotide LAR in Severe Polycystic Liver Disease
Conditions: Somatostatin Analogs;   Polycystic Liver Disease;   Autosomal Dominant Polycystic Kidney Disease;   Autosomal Dominant Polycystic Liver Disease
Interventions: Drug: Pasireotide LAR;   Drug: Placebo
19 Recruiting Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease
Conditions: Polycystic Liver Disease (PLD):;   Polycystic Kidney, Autosomal Dominant;   Polycystic Liver Disease
Intervention: Drug: Ursodeoxycholic Acid
20 Completed Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety
Condition: Polycystic Kidney
Interventions: Drug: Sirolimus;   Drug: conventional therapy

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years